Sort

Search

01/03/2026 Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital
Herrera, IC, Cols, LC, Pijuan-Andujar, L, Cajo, SA, Montalvan, RG, Calvente, MG, Luque, GA, Gallardo, A, Jaramillo, JFC. Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105990. PMID:. IF:4.200(Q1/1D).
01/03/2026 Serous Tubal Intraepithelial Carcinoma (STIC): Incidence and Clinical Implications in 254 Consecutive Cases from a Tertiary Care Hospital
Misad, C, Cajo, SA, Espadaler, I, Muñoz, R, D'Angelo, E, Gallardo, A, Espinosa, I, Prat, J. Serous Tubal Intraepithelial Carcinoma (STIC): Incidence and Clinical Implications in 254 Consecutive Cases from a Tertiary Care Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105314. PMID:. IF:4.200(Q1/1D).
01/03/2026 ctDNA clearance after induction therapy as predictor of response to radical chemoradiotherapy in locally advanced head and neck cancer
Bruixola, G, Martín-Arana, J, Vidales, Z, Peon, G, Gimeno-Valiente, F, Tous, S, Camblor, DG, Cirauqui, B, García-Bartolomé, M, Sumarroca, A, Martínez-Castedo, B, Leon, X, Micó-García, B, Iglesias-Martínez, B, García-March, A, Segui, V, Pavón, MA, Quirós, B, Clavero, O, Maroñas, M, Escorihuela-Garcia, V, Tarazona, N, Alemany, L, Oliva, M. ctDNA clearance after induction therapy as predictor of response to radical chemoradiotherapy in locally advanced head and neck cancer. RADIOTHERAPY AND ONCOLOGY. 2026; 216DOI:. PMID:. IF:5.300(Q1/2D).
01/03/2026 Cochlear implant failures and complications: What should radiologists look for?
Moreno, EG, Pizarro, MPV, Dotu, CO, Martínez, AL, Escalante, JEM, Beltran, JD. Cochlear implant failures and complications: What should radiologists look for?. Radiologia. 2026; 68(2)DOI:10.1016/j.rx.2025.501685. PMID:. IF:(Q/D).
01/03/2026 Clinical and Economic Implications of Immunoglobulin Use Under Restrictive Conditions in Adult Patients With Neurological Diseases and Immunodeficiencies in Spain
Querol, L, Montoro-Ronsano, JB, Soler-Palacín, P, Galduf, J, Martínez-Pérez, O, Díaz-Cuervo, H. Clinical and Economic Implications of Immunoglobulin Use Under Restrictive Conditions in Adult Patients With Neurological Diseases and Immunodeficiencies in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2026; 33(3)DOI:10.1111/ene.70570. PMID:41834317. IF:3.900(Q1/3D).
01/03/2026 Central nervous system disorders following haematopoietic stem cell transplantation: a prospective case-control observational study from the Infectious Diseases Working Party and the Transplant Complications Working Party of EBMT
Schmidt-Hieber, M, Ljungman, P, Gilbert, P, Knelange, N, Drozd-Sokolowska, J, Basak, G, Einsele, H, Tridello, G, Abdeljelil, NB, Kulagin, A, Balaguer-Rosello, A, Metafuni, E, Faraci, M, Gozdzik, J, Martino, R, Raiola, AM, Xhaard, A, Kuskonmaz, B, Biffi, A, Czyzewski, K, Gabriel, MA, Martínez-Lopez, J, Zaidman, I, Schlegel, PG, Gruhn, B, Krivan, G, Vicent, MG, Mikulska, M, Peric, Z, Averbuch, D, Styczynski, J, Penack, O, de la Camara, R. Central nervous system disorders following haematopoietic stem cell transplantation: a prospective case-control observational study from the Infectious Diseases Working Party and the Transplant Complications Working Party of EBMT. Eclinicalmedicine. 2026; 93DOI:10.1016/j.eclinm.2026.103792. PMID:41783087. IF:10.000(Q1/1D).
01/03/2026 Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects
Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Espinàs, JA, Borras, JM. Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04022-9. PMID:40900393. IF:2.500(Q3/6D).
01/03/2026 Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia
Mecklenbrauck, R, Ramiro, AV, Sträng, E, Gabdoulline, R, Elicegui, JM, Sobas, M, Pleyer, L, Turki, A, Voso, MT, Benner, A, Hernández-Sánchez, A, Tettero, JM, Gimenez, LT, Metzeler, KH, Oñate, G, Lehmann, S, Huntly, BJP, Thomas, I, Thol, FR, Heidel, FH, Valk, PJM, Döhner, K, Haferlach, T, Mills, KI, Döhner, H, Castellani, G, Ossenkoppele, GJ, Hernández-Rivas, JM, Bullinger, L, Heuser, M. Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. LEUKEMIA. 2026; 40(3)DOI:10.1038/s41375-026-02874-w. PMID:41663622. IF:13.400(Q1/1D).
01/03/2026 The precision of a report on precision
Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Piñol, JAE, Borras, JM. The precision of a report on precision. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-026-04219-6. PMID:41610006. IF:2.500(Q3/6D).
01/03/2026 Subphenotype-and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials
Escrihuela-Vidal, F, Larrauri, JG, López-Contreras, J, Euba, G, Vázquez, A, Gómez-Zorrilla, S, López-Cortés, LE, Gasch, O, Aparicio-Minguijón, E, Escudero-Sànchez, R, Pérez-Rodríguez, MT, Rodríguez-Pardo, D, Jover-Sáenz, A, García-Pardo, G, Rodríguez-Baño, J, Pujol, M, Carratalà, J, Gutiérrez-Gutiérrez, B. Subphenotype-and complication-guided adjunctive fosfomycin versus standard monotherapy in Staphylococcus aureus bacteraemia: pooled analysis of two randomised trials. Lancet Regional Health-Europe. 2026; 62DOI:10.1016/j.lanepe.2026.101611. PMID:41788427. IF:13.000(Q1/1D).
01/03/2026 Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.
Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).
01/03/2026 Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.
Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).
01/03/2026 SEOM-AEEMT consensus on occupational cancer and cancer-associated disability
Mezquita, L, Vicente-Herrero, MT, Cruz, P, de la Torre, MVRI, Hidalgo-Coloma, J, Garcia, LC, Gallego, O, Calvo, A, Martinez, K, Perez-Altozano, J, Molina, R, Garcia-Pardo, M, Gutierrez-Sainz, L, Moreno-Atahonero, E, Ore-Arce, M, Serrano, C, Terradillos-Garcia, MJ, Valero, MR, Reinoso-Barbero, L, Rodriguez, CA, Calvo-Cerrada, B. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04037-2. PMID:40956506. IF:2.500(Q3/6D).
01/03/2026 REAL-WORLD EVIDENCE FOR FIXED TRIPLE THERAPY WITH BECLOMETHASONE/FORMOTEROL/GLYCOPYRRONIUM IN ASTHMA PATIENTS WITH CONCOMITANT COPD: SIX-MONTH RESULTS OF TRIMAXIMIZE
Harniman, K, Gessner, C, Bogoevska, V, Russell, R, Ulrik, CS, Pohl, W, Plaza, V, Bourdin, A, Fritz, C, Hahn, A, Trinkmann, F. REAL-WORLD EVIDENCE FOR FIXED TRIPLE THERAPY WITH BECLOMETHASONE/FORMOTEROL/GLYCOPYRRONIUM IN ASTHMA PATIENTS WITH CONCOMITANT COPD: SIX-MONTH RESULTS OF TRIMAXIMIZE. INTERNAL MEDICINE JOURNAL. 2026; 56DOI:. PMID:. IF:1.500(Q2/5D).
01/03/2026 SEPAR Recommendations on Vaccination for Chronic Respiratory Patients
de Miguel-Díez, J, Torres-Castro, R, Herrero, FS, Villanueva, RM, Gómez, BS, Fernández, SQ, Rojo, RP, Cuesta, VMM, Castillo, ME, Fernández, LS, Martínez, MMC, Mediano, O, García-Ortega, A, Rivero, JLG, de la Rosa-Carrillo, D. SEPAR Recommendations on Vaccination for Chronic Respiratory Patients. ARCHIVOS DE BRONCONEUMOLOGIA. 2026; 62(3)DOI:10.1016/j.arbres.2025.06.005. PMID:40592680. IF:9.200(Q1/1D).
01/03/2026 Interpretable Artificial Intelligence Model for the Automatic Identification of Botryoid Neutrophils
Merino, A, Barrera, K, Verdú, G, San José, P, Vallbé, M, Molina, A, Rodellar, J. Interpretable Artificial Intelligence Model for the Automatic Identification of Botryoid Neutrophils. International Journal of Laboratory Hematology. 2026; 48DOI:. PMID:. IF:2.300(Q2/5D).
01/03/2026 GRADE Guidance: Update on Developing Good Practice Statements in Guidelines
Dewidar, O, Akl, EA, Morgano, GP, Parmelli, E, Saz-Parkinson, Z, Langendam, MW, Meerpohl, JJ, Marti, M, Mayer, M, Djulbegovic, B, Brignardello-Petersen, R, Chu, DK, Murad, MH, Canelo-Aybar, C, Mathew, JL, Alonso-Coello, P, Qaseem, A, Schwingshackl, L, Bognanni, A, Rojas-Reyes, MX, Morgan, RL, Klugar, M, Comas, DR, Stallings, E, Iorio, A, Tugwell, P, Darzi, A, Turgeon, AF, Shamliyan, TA, Munn, Z, Mathioudakis, AG, Piggott, T, Lotfi, T, Pottie, K, Guyatt, G, Schünemann, HJ. GRADE Guidance: Update on Developing Good Practice Statements in Guidelines. ANNALS OF INTERNAL MEDICINE. 2026; 179(3)DOI:10.7326/ANNALS-25-00431. PMID:41554128. IF:15.200(Q1/1D).
01/03/2026 Impact of matrix-construction assumptions on quantitative overlap assessment in overviews: A meta-research study
Bracchiglione, J, Meza, N, Pieper, D, Lunny, C, Vargas-Peirano, M, Vicuña, J, Briceño, F, Parra, RG, Carrasco, IP, Urrútia, G, Bonfill, X, Madrid, E. Impact of matrix-construction assumptions on quantitative overlap assessment in overviews: A meta-research study. Research Synthesis Methods. 2026; 17(2)DOI:10.1017/rsm.2025.10056. PMID:41635949. IF:6.100(Q1/1D).
01/03/2026 Integrating planetary health considerations into health guidelines: decision-making bodies must show leadership
Metzendorf, MI, Aloosh, M, Benton, L, Perez, JB, Cumpston, M, de'Donato, FK, Laot, S, Piggott, T, Rahman, KMSU, Stein, AT. Integrating planetary health considerations into health guidelines: decision-making bodies must show leadership. Bmj Leader. 2026; 10(1)DOI:10.1136/leader-2025-001277. PMID:40730455. IF:(Q/D).
01/03/2026 Screening for lung cancer: A systematic review of overdiagnosis and its implications
Fernández-Sáenz, FK, de la Torre-Perez, L, Baldwin, DR, van der Aalst, C, Thorat, M, Ritchie, D, Carvalho, AL, Espina, C, Solà, I, Canelo-Aybar, C, Pissinis, MM, Alonso-Coello, P, Pinto, ACPN. Screening for lung cancer: A systematic review of overdiagnosis and its implications. Molecular Oncology. 2026; 20(3)DOI:10.1002/1878-0261.70139. PMID:41220098. IF:4.500(Q2/3D).